Monte Rosa Therapeutics, Inc. (GLUE) vs MannKind Corporation (MNKD)

Monte Rosa Therapeutics, Inc. and MannKind Corporation are both Biotechnology companies. Monte Rosa Therapeutics, Inc. and MannKind Corporation are of similar size ($1.1B and $999.9M). MannKind Corporation grew revenue faster over the last twelve months: 30.5% against −83.9%. MannKind Corporation has the higher net margin (−11.1% vs −560.9%) and the higher return on invested capital (2.36% vs 0.00%). Across the 16 metrics below, MannKind Corporation leads on 13 and Monte Rosa Therapeutics, Inc. on 3.

Valuation

Metric GLUE MNKD Biotechnology median
P/E n/m n/m 7.88
P/S 41.58 2.62 11.47
P/B 2.45 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 42.70 0.74
EV/Sales 19.96 3.41 10.73
Earnings yield (14.95%) (3.89%) (28.84%)
Free cash flow yield (2.69%) (1.76%) (23.03%)

Profitability

Metric GLUE MNKD Biotechnology median
Gross margin 100.00% 75.39% 65.16%
Operating margin (633.04%) 2.34% 0.00%
Net margin (560.85%) (11.08%) 0.00%
Free cash flow margin (111.66%) (4.61%) 0.00%
Return on equity (42.66%) 71.36% (57.72%)
Return on assets (30.67%) (7.62%) (49.22%)
Return on invested capital 0.00% 2.36% 0.00%

Growth

Metric GLUE MNKD Biotechnology median
Revenue growth (TTM) (83.86%) 30.46% 5.64%
EPS growth (last fiscal year) 53.06% (80.00%) —
Revenue growth, 5-year CAGR — 39.89% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GLUE MNKD Biotechnology median
Debt to equity 0.00 (6.28) 0.00
Current ratio 10.58 1.72 4.73
Net debt to EBITDA 8.22 5.32 0.96

Dividend

Metric GLUE MNKD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GLUE MNKD Biotechnology median
Market cap 999.87m 1.06b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack